Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It caused the highly contagious disease called coronavirus disease 2019 (COVID-19), declared a global pandemic by the World Health Organization (WHO) on 11 March 2020. A great number of studies in the search of new therapies and vaccines have been carried out in these three long years, producing a series of successes; however, the need for more effective vaccines, therapies and other solutions is still being pursued. This review represents a tracking shot of the current pharmacological therapies used for the treatment of COVID-19.
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference98 articles.
1. WHO (2022, November 14). WHO Coronavirus (COVID-19) Dashboard, Available online: https://covid19.who.int/.
2. Iacopetta, D., Ceramella, J., Catalano, A., Saturnino, C., Pellegrino, M., Mariconda, A., Longo, P., Sinicropi, M.S., and Aquaro, S. (2022). COVID-19 at a glance: An up-to-date overview on variants, drug design and therapies. Viruses, 14.
3. Confronting the Delta variant of SARS-CoV-2, summer 2021;Malani;JAMA,2021
4. Lewnard, J.A., Hong, V., and Tartof, S.Y. (2022). Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. medRxiv.
5. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies;Sheward;Lancet Infect. Dis.,2022
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献